• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Adjunctive nivolumab reduces risk of death and progression of gastric adenocarcinoma compared to chemotherapy alone

byJessie WillisandTeddy Guo
July 13, 2021
in Chronic Disease, Gastroenterology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Overall survival and progression-free survival were higher for patients on nivolumab plus chemotherapy compared to chemotherapy alone.

2. Severe adverse events occurred more frequently in the nivolumab group and more patients withdrew from treatment due to these events.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The 5-year survival rate of patients with proximal gastric cancer is approximately 10-15%. Nivolumab is a cancer therapy which inhibits PD-ligand 1 (PD-L1), a highly expressed surface molecule on tumour cells that allow them to evade the host immune system. Previous trials of nivolumab in gastric cancer have shown increased efficacy in patients with increased combined positive score (CPS), which is a measure of PD-L1 expression on tumour-related cells. This study was a phase 3 trial comparing the safety and efficacy of chemotherapy alone versus chemotherapy and nivolumab in gastric adenocarcinoma. Patients in 29 countries across Asia, Australia, Europe, North America, and South America were randomized 1:1 to the two treatment groups. Results showed significant reduction in risk of progression and death in the nivolumab group compared to chemotherapy alone, with a greater reduction in patients with CPS of greater than five. However, severe adverse events occurred more frequently in patients on nivolumab plus chemotherapy. While treatment-related risk of death was low, 16 patients died in the nivolumab group versus four in the chemotherapy group. Limitations of this study include an open-label design, variable treatment regimens of nivolumab, and large amounts of patients discontinuing treatment due to adverse events. Nonetheless, this study provides a large dataset which supports the use of nivolumab, especially in patients with high CPS.

Click to read the study in the Lancet

Relevant Reading: Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

In-Depth [randomized controlled trial]: From March 27, 2017 and April 24, 2019, 1581 patients were randomly assigned to receive chemotherapy alone (n=789) or chemotherapy plus 360 mg nivolumab every 3 weeks or 240 mg every 2 weeks (n=789). Eligibility criteria included ages ≥18 years, previously untreated, unresectable, non-HER2-positive gastric, gastro-esophageal junction, or esophageal adenocarcinoma. Primary endpoints were overall survival (OS) or progression-free survival (PFS) in only those patients with PD-L1 combined positive score (CSP) of five or more. Tumours were measured by CT or MRI throughout the study. Compared to chemotherapy alone, in those with CPS ≥5, patients on adjunctive nivolumab had significantly improved OS (HR 0.71, p<0.0001) and PFS (HR 0.68, p < 0.0001). Similar findings were seen in patients with CPS ≥1, though not all outcomes were formally tested for significance. Grade 3-4 treatment-related adverse events were experienced by 59% of those in the nivolumab group and 44% in the chemotherapy group. Treatment-related deaths were 16 in the nivolumab group and 4 in the chemotherapy group alone.

RELATED REPORTS

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

#VisualAbstract: Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adenocarcinomaanti-PD-1anti-PD-L1chemotherapyesophageal adenocarcinomaesophageal cancergastroesophageal cancergastroesophageal junction cancermonoclonal antibodyNivolumab
Previous Post

Platelet-rich plasma injection does not significantly improve chronic midportion Achilles tendinopathy outcomes

Next Post

Diminished age-related decline of the amygdala in long-term meditation practitioners

RelatedReports

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
StudyGraphics

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

May 18, 2022
Dacomitinib may be effective in EGFR-associated lung cancer
Chronic Disease

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

May 9, 2022
#VisualAbstract: Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer
StudyGraphics

#VisualAbstract: Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer

April 28, 2022
#VisualAbstract: Ruxolitinib use may be associated with higher incidences of nonmelanoma skin cancers
StudyGraphics

#VisualAbstract: Trastuzumab does not improve survival in patients with esophageal adenocarcinoma with HER2 overexpression

April 27, 2022
Next Post
Brain lesions on MRI linked with subsequent increased stroke risk

Diminished age-related decline of the amygdala in long-term meditation practitioners

Amyloidogenic genetic variant not associated with increased mortality in blacks

Daratumumab therapy addition improved response in systemic immunoglobulin light-chain amyloidosis

#VisualAbstract: Metformin use is associated with a decreased risk of basal cell carcinoma

#VisualAbstract: Metformin use is associated with a decreased risk of basal cell carcinoma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Wellness Check: Sleep
  • Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events
  • Early onset Lewy Body Dementia is more clinically distinct from Alzheimer Dementia than late onset Lewy Body Dementia
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.